High density lipoprotein subfractions during continuous insulin infusion therapy.

Area of Science:

• Endocrinology
• Metabolic Disorders
• Cardiovascular Health

Background:

• Type 1 diabetes mellitus (T1DM) management often involves balancing glycemic control with metabolic health.
• Lipid and lipoprotein profiles are crucial indicators of cardiovascular risk in diabetic patients.
• Conventional insulin therapy (CIT) and continuous subcutaneous insulin infusion (CSII) represent different approaches to insulin delivery.

Purpose of the Study:

• To compare the effects of CSII versus CIT on serum lipid and lipoprotein levels in T1DM patients.
• To evaluate changes in high-density lipoprotein cholesterol (HDL-chol) subfractions (HDL2-chol and HDL3-chol) under different insulin therapies.
• To determine the relationship between glycemic control (HbA1) and lipid profile alterations.

Main Methods:

• A 1-year cross-over study involving 28 normolipidemic, nonobese T1DM patients.
• Patients were treated with 6 months of CSII followed by 6 months of CIT, or vice versa.
• Serum lipid and lipoprotein levels, including HDL-cholesterol subfractions, were monitored throughout the study.

Main Results:

• CSII significantly improved glycemic control (HbA1) compared to CIT.
• HDL-cholesterol increased by 38% with CSII and 18% with CIT, primarily due to increases in HDL2-chol and HDL3-chol.
• CSII led to a further rise in HDL2-chol, while CIT decreased HDL3-chol. No significant changes were observed in VLDL or LDL lipids.

Conclusions:

• CSII therapy, even with modest glycemic improvement, is associated with a significant increase in HDL-cholesterol, particularly the cardioprotective HDL2 subfraction.
• CSII may offer advantages over CIT in improving lipid profiles relevant to cardiovascular health in T1DM.
• The findings highlight the potential benefits of advanced insulin delivery systems for managing metabolic complications in type 1 diabetes.